6 results
A better understanding on the individual response to different albuminuria lowering drugs and a better understanding why these drugs, of which some are developed for another indication, may help to tailor optimal therapy. Therefore in this study…
The aim of this trial is to individualize and thus to optimize treatment for each patient by adapting it to the individual response. The treatment response is determined by means of FDG-PET after 2 cycles of escalated BEACOPP + 2 cycles of ABVD.The…
Primary objective: What are the long-term effects (i.e. after 8-week drug exposure) of the DPP-4i linagliptin versus the SU derivative glimepiride on fasting and postprandial renal hemodynamics (glomerular filtration rate (GFR)/ effective renal…
PrimaryTo evaluate the long-term safety and tolerability of baricitinib in patients with SLE.
To evaluate the effect of baricitinib 4-mg QD and background standard-of-care therapy compared with placebo and background standard-of-care therapy on SLE disease activity.
The primary objective is to test the hypothesis that baricitinib high dose level in combination with topical corticosteroids (TCS) or baricitinib medium dose level in combination with TCS is superior to placebo in combination with TCS in the…